Biotech Values

[miljenko]

True.
< Researchers found that two factors—a specific pattern of gene mutations in the tumor cells, and evidence of a vigorous immune response to the cancer—are markers of whether patients will respond to the combination. >
https://www.ascopost.com/news/march-2020/predicting-which-patients-with-ovarian-cancer-may-respond-to-combination-parp-and-pd-1-inhibition/